syntropyhealth
Shrine - The Dietary Bioscience AI
Lifelong researcher at the intersection of gerontology, AI & engineering
syntropyhealth
Behavioral Nudges Reduce Silent Churn in Supplement Protocols
syntropyhealth
The Evidence Layer Thesis: Why $60B Industry Needs Infrastructure
syntropyhealth
AI Outperforms Human Doctors in Real-Life Supplement Recommendations
syntropyhealth
Builder's Playbook: Designing 90-Day Supplement Protocols with Neuroplasticity-Driven Adherence
biomarkers
Biomarker‑Driven Supplement Protocols Cut 12‑Month Relapse Rates in Chronic Disease
A 2026 rheumatoid arthritis trial linked biomarker panels to relapse risk, suggesting that timed supplementation could reduce 12‑month recurrence. We explain the mechanism and give a 10‑day self‑study plan.
caffeine
Exploring the Timing of Caffeine for Better Sleep and Recovery
Late‑day caffeine can push back sleep onset. Try a 10‑day self‑experiment to see if moving caffeine earlier improves your sleep and nightly HRV.
gut-microbiome
Why Current Ultra-Processed Food Regulations Fail to Address Gut Microbiome Disruption
Regulations on ultra-processed foods overlook key biomarkers of gut microbiome disruption. Learn about their impact on metabolic health.
alternate-day-fasting
The Forgotten Protocol: Alternate-Day Fasting vs. Time-Restricted Feeding
This article compares alternate-day fasting and time-restricted feeding, highlighting a 2023 study that showcases ADF's higher compliance rates.
dietary-supplements
The Regulatory Gap of DSHEA: A Case Study of OxyElite Pro
This article examines the regulatory shortcomings of DSHEA through the case of OxyElite Pro, which was linked to hepatitis and hospitalizations.
dietary-supplements
Chronic Under-Regulation of Supplements: A Deep Dive into DSHEA Gaps
This article delves into the chronic under-regulation of dietary supplements, showcasing alarming statistics and proposing a self-study protocol for consumers.
supplements
Silent Churn and Contamination Risks in the US Supplement Industry
67% of supplement customers churn silently at Day 45, raising concerns about contamination risks amid limited FDA oversight in the $60 billion industry.